Abstract
Psoriasis is a chronic inflammatory skin disease caused by multiple factors. With the widespread use of biological agents, the therapeutic effect of psoriasis is gradually recognized, among which interleukin-17A (IL-17A) inhibitor has remarkable efficacy, which has aroused great attention in the academic world. However, some cases abroad have shown that IL-17A inhibitors may induce or secondary to other skin diseases in the treatment of psoriasis. In this review, we will review the case reports of other skin diseases induced or secondary to IL-17A inhibitors in the treatment of psoriasis in recent years, in order to provide a reference for clinicians in the use of this drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
